| Rebif (human IFN-β-1a) / EMD Serono |
| Completed | N/A | 36 | US | | EMD Serono, Pfizer | Multiple Sclerosis | 10/07 | 02/08 | | |
STAR, NCT01080027: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings |
|
|
| Completed | N/A | 254 | Europe | Rebif® New Formulation, Interferon beta1-A | Merck KGaA, Darmstadt, Germany, Merck A.E., Greece, Merck OY, Finland, Merck B.V., Netherlands, Merck A.B., Sweden, Merck, S.A., Portugal | Multiple Sclerosis, Relapsing Remitting | 06/11 | 06/11 | | |
Leptin, NCT01067573: The Role of Serum Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment |
|
|
| Completed | N/A | 20 | US | | University of South Florida, EMD Serono | Multiple Sclerosis | | 07/11 | | |
REPLAY, NCT01207648: Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects |
|
|
| Completed | N/A | 307 | US, Canada, Europe, RoW | Rebif® | EMD Serono | Multiple Sclerosis | 07/11 | 07/11 | | |
NCT00914758: Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS) |
|
|
| Unknown status | N/A | 1 | US | | Washington Neuropsychology Research Group, Genzyme, a Sanofi Company | Relapsing Remitting Multiple Sclerosis | 10/11 | 12/11 | | |
SCANSMART, NCT01125475: A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects |
|
|
| Completed | N/A | 61 | Europe | RebiSmart | Merck KGaA, Darmstadt, Germany, Merck Serono Norway, Smerud Medical Research International AS | Relapsing Remitting Multiple Sclerosis (RRMS) | 03/12 | | | |
|
NCT01112345: An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters |
|
|
| Completed | N/A | 133 | Europe | | Merck KGaA, Darmstadt, Germany, Merck A.E., Greece | Multiple Sclerosis, Relapsing-Remitting | 09/12 | 09/12 | | |
READER, NCT01601080: An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device |
|
|
| Completed | N/A | 230 | Europe | | Merck KGaA, Darmstadt, Germany, Merck Serono Limited, UK | Relapsing Multiple Sclerosis | 10/12 | | | |
| Completed | N/A | 2878 | US | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b, Copaxone®, Avonex®, Rebif®, Betaseron® | Teva Neuroscience, Inc. | Multiple Sclerosis | 12/12 | 01/13 | | |
|
|
|
|
|
|
|
|
SMART, NCT01108887: An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. |
|
|
| Completed | N/A | 912 | Europe | | Merck KGaA, Darmstadt, Germany, Merck Serono S.A., Geneva | Multiple Sclerosis, Relapsing-Remitting | 01/13 | 01/13 | | |
|
|
ReNew, NCT01101776: Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. |
|
|
| Completed | N/A | 49 | RoW | Interferon beta-1a (Rebif), Rebif New Formulation | Merck KGaA, Darmstadt, Germany, Merck Serono Australia Pty Ltd | Multiple Sclerosis | 04/13 | 04/13 | | |
SKORE, NCT01075880: Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® |
|
|
| Completed | N/A | 300 | Europe | Rebif (Interferon beta-1a), Rebif | Merck KGaA, Darmstadt, Germany, Merck spol.s.r.o., Czech Republic | Multiple Sclerosis, Relapsing-Remitting | 06/13 | 06/13 | | |
| Completed | N/A | 198 | Canada | RebiSmart™, Rebif | Merck KGaA, Darmstadt, Germany, EMD Inc., Canada | Multiple Sclerosis, MS | 04/14 | 04/14 | | |
|
|
EMR200136_550, NCT01601119: Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients |
|
|
| Completed | N/A | 545 | Europe | Rebif, Other: Disease modifying therapies (DMT) | Merck KGaA, Darmstadt, Germany, Merck Serono Limited, UK | Relapsing Multiple Sclerosis | 07/14 | 07/14 | | |
| Terminated | N/A | 306 | US | Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B | EMD Serono | Multiple Sclerosis, Relapsing-Remitting | 01/15 | 01/15 | | |
| Completed | N/A | 296 | Canada | MACFIMS, MSQoL-54 | Centre hospitalier de l'Université de Montréal (CHUM), EMD Serono Canada Inc. | Multiple Sclerosis | 05/15 | 12/16 | | |
NCT02419638: Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS |
|
|
| Withdrawn | N/A | 0 | US | Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate) | Brigham and Women's Hospital, EMD Serono | Multiple Sclerosis | 12/15 | 02/16 | | |
PROTRACT, NCT02823951: Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® |
|
|
| Completed | N/A | 479 | US, Canada | Rebif, Tecfidera | IMS HEALTH GmbH & Co. OHG, EMD Serono | Relapsing-remitting Multiple Sclerosis | 04/17 | 02/18 | | |
MESTRE-MS, NCT02949908: MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) |
|
|
| Terminated | N/A | 2 | Europe | Rebif, IFNβ-1b | Merck KGaA, Darmstadt, Germany, Merck B.V., Netherlands | Multiple Sclerosis | 08/17 | 08/17 | | |
| Completed | N/A | 34 | US | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Relapsing-Remitting Multiple Sclerosis | 05/18 | 05/18 | | |
| Completed | N/A | 2089 | Europe | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd, Plegridy (peginterferon beta-1a), Biogen Idec Ltd, Avonex (interferon beta-1a), Biogen Idec Ltd, MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046), No MSDMDs therapy (control) | Bayer, EPID Research, Biogen, Merck Serono Europe Ltd, Novartis Pharmaceuticals | Multiple Sclerosis | 08/18 | 08/18 | | |
PERFECT, NCT03347370: A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis |
|
|
| Completed | N/A | 626 | Europe | SC Peginterferon beta-1a, Plegridy, SC interferon beta-1a, Rebif, SC interferon beta-1b, Betaferon, Extavia | Biogen, AMS Advanced Medical Services GmbH | Multiple Sclerosis, Relapsing-Remitting | 07/19 | 07/19 | | |
| Completed | N/A | 594 | Europe, RoW | Rebif (Interferon beta-1a) | Merck KGaA, Darmstadt, Germany, Merck Serono Middle East FZ LLC | Relapsing Multiple Sclerosis (RMS) | 07/20 | 07/20 | | |
INFORM, NCT06053749: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden |
|
|
| Not yet recruiting | N/A | 100 | Europe | Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs) | Bayer, Biogen Netherlands B.V, Novartis Europharm Limited, Merck Europe B.V. | Multiple Sclerosis (MS) | 03/26 | 03/26 | | |
